Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Omeros is a commercial-stage biotechnology company focused on complement-mediated diseases, cancers, and addictive disorders. The company recently achieved a major milestone with the FDA approval of YARTEMLEA (narsoplimab) on December 23, 2025, for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Commercial sales commenced in January 2026.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Loss (Continuing Ops) | $(4.8) million | $(182.6) million |
| Net Loss (Total) | $(3.4) million | $(156.8) million |
| Research & Development Expenses | $81.3 million | $119.5 million |
| Selling, General & Admin Expenses | $41.5 million | $47.4 million |
| Cash, Cash Equivalents & Short-Term Investments | $171.8 million | $90.1 million |
| Total Debt (Principal) | $87.9 million | $164.9 million |
| Operating Cash Flow | $(116.1) million | $(148.8) million |
Note: The 2025 results include a significant non-cash loss of $136.7 million related to the remeasurement of embedded derivatives on convertible notes and a $237.6 million gain on the sale of zaltenibart.
Material Changes vs. Prior Period
- Asset Sale Transaction: On November 25, 2025, Omeros sold exclusive global rights to its MASP-3 inhibitor, zaltenibart, to Novo Nordisk. The company received an upfront cash payment of $240.0 million and recorded a gain of $237.6 million. Omeros retains rights to its MASP-3 small-molecule program.
- Debt Restructuring: The company repaid its $67.1 million Term Loan in full using proceeds from the zaltenibart sale. Additionally, $70.8 million of 2026 Notes were exchanged for new 2029 Notes, and $10.0 million of 2026 Notes were converted to equity. The remaining 2026 Notes ($17.1 million) matured and were repaid in February 2026.
- Derivative Remeasurement: Due to a significant increase in stock price following the FDA approval and asset sale, the company recorded a $134.2 million non-cash loss on the remeasurement of the embedded derivative associated with the 2029 Notes.
- Expense Reduction: R&D expenses decreased by $38.2 million year-over-year, primarily due to the transfer of zaltenibart development costs to Novo Nordisk and the closure of certain clinical programs.
Guidance, Outlook, and Risks
- Commercial Launch: Omeros is actively commercializing YARTEMLEA in the U.S. with a deployed field force. The company expects SG&A expenses to increase in 2026 to support commercial infrastructure and marketing.
- Liquidity: Management expects to fund more than 12 months of operations using current cash balances ($171.8 million) and anticipated revenue from YARTEMLEA sales.
- Future Milestones: Omeros is eligible for up to $1.8 billion in potential development and commercial milestones plus tiered royalties from Novo Nordisk based on zaltenibart performance.
- Key Risks:
- Commercialization Success: Profitability is highly dependent on the market acceptance and reimbursement of YARTEMLEA.
- Regulatory Approval: A Marketing Authorization Application (MAA) for YARTEMLEA is under review by the European Medicines Agency (EMA); approval is not guaranteed.
- Derivative Volatility: The fair value of the embedded derivative on the 2029 Notes is sensitive to stock price fluctuations, which could result in significant non-cash gains or losses in future periods.
- Manufacturing: The company relies entirely on third-party contract manufacturers (Lonza and Vetter) for YARTEMLEA production.
Investor Verification Checklist
- YARTEMLEA Sales Data: Verify initial commercial uptake and reimbursement rates in Q1 2026 to assess revenue trajectory.
- EMA Decision Timeline: Monitor the status of the European Medicines Agency review for YARTEMLEA to gauge international expansion potential.
- Stock Price Sensitivity: Review the impact of stock price volatility on the quarterly remeasurement of the 2029 Note embedded derivative liability.
- Novo Nordisk Milestones: Track the development progress of zaltenibart under Novo Nordisk to estimate the timing of potential milestone payments.
- Debt Maturity: Confirm the repayment of the remaining 2026 Notes (completed Feb 2026) and the terms of the outstanding 2029 Notes.